What do systematic reviews say?

Rivastigmine vs placebo

Cholinesterase inhibitors (rivastigmine) showed no clear difference in mortality compared with placebo (low certainty).

• Cholinesterase inhibitors for the treatment of delirium in non‐ICU settings 2018 · Cochrane Headline outcomes only
  RR 0.1 [0.01, 1.56]
  1 study · 15 participants
  Low

Rivastigmine vs placebo

The review found no eligible studies for this question.

• Cholinesterase inhibitors for the treatment of delirium in non‐ICU settings 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Phosphodiesterase inhibitors vs placebo

• Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 111 participants
  Low

Phosphodiesterase inhibitors vs placebo

• Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 111 participants
  Very low

Phosphodiesterase inhibitors vs placebo

• Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 73 participants
  Low

Phosphodiesterase inhibitors vs placebo

The review found no eligible studies for this question.

• Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Phosphodiesterase inhibitors vs placebo

• Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 138 participants
  GRADE not reported

Phosphodiesterase inhibitors vs placebo

• Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 79 participants
  Low

Prophylactic cholinesterase inhibitor vs placebo

• Interventions for preventing delirium in hospitalised non‐ICU patients 2016 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 128 participants
  Low

Prophylactic cholinesterase inhibitor vs placebo

The review found no eligible studies for this question.

• Interventions for preventing delirium in hospitalised non‐ICU patients 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prophylactic cholinesterase inhibitor vs placebo

The review found no eligible studies for this question.

• Interventions for preventing delirium in hospitalised non‐ICU patients 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prophylactic cholinesterase inhibitor vs placebo

It is very uncertain whether prophylactic cholinesterase inhibitor changes incidence of delirium DSM‐IV criteria, DSI, CAM, compared with placebo (very low certainty).

• Interventions for preventing delirium in hospitalised non‐ICU patients 2016 · Cochrane Headline outcomes only
  RR 0.68 [0.17, 2.62]
  2 studies · 113 participants
  Very low

Prophylactic cholinesterase inhibitor vs placebo

The review found no eligible studies for this question.

• Interventions for preventing delirium in hospitalised non‐ICU patients 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prophylactic cholinesterase inhibitor vs placebo

• Interventions for preventing delirium in hospitalised non‐ICU patients 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 16 participants
  Low

Summary of findings for cholinesterase inhibitors vs placebo

• Interventions for preventing falls in Parkinson's disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 121 participants
  Very low

Summary of findings for cholinesterase inhibitors vs placebo

Summary of findings for cholinesterase inhibitors may leads to higher rate of adverse events excluding falls (per person year) compared with placebo (low certainty).

• Interventions for preventing falls in Parkinson's disease 2022 · Cochrane Headline outcomes only
  Rate ratio 1.6 [1.28, 2.01]
  2 studies · 175 participants
  Low

Summary of findings for cholinesterase inhibitors vs placebo

The review found no eligible studies for this question.

• Interventions for preventing falls in Parkinson's disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings for cholinesterase inhibitors vs placebo

Summary of findings for cholinesterase inhibitors may leads to lower rate of falls (falls per person‐year) compared with placebo (low certainty).

• Interventions for preventing falls in Parkinson's disease 2022 · Cochrane Headline outcomes only
  Rate ratio 0.5 [0.44, 0.58]
  3 studies · 229 participants
  Low

Summary of findings for cholinesterase inhibitors vs placebo

• Interventions for preventing falls in Parkinson's disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 230 participants
  Very low

Summary of findings for cholinesterase inhibitors vs placebo

• Interventions for preventing falls in Parkinson's disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 23 participants
  Very low